{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T09:51:56Z","timestamp":1700387516118},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Big Data"],"abstract":"Abstract<\/jats:title>Hepatocellular carcinoma (HCC) represents a formidable malignancy with a high lethality. Nonetheless, the development of vaccine and the establishment of prognostic models for precise and personalized treatment of HCC still encounter big challenges. Thus, the aim of this study was to develop HCC vaccines and explore anoikis-based prognostic models based on RNA sequencing data in GEO datasets (GSE10143, GSE76427) and the TCGA-LIHC cohort. Potential HCC antigens were identified using GEPIA2, cBioPortal, and TIMER2. Anoikis-related subtypes and gene clusters were defined by consensus clustering of 566 liver cancer samples based on 28 anoikis regulators, and we further analyzed their relationship with the immune microenvironment of HCC. A predictive model based on anoikis-related long noncoding RNAs (lncRNAs) was developed to accurately predict HCC prognosis. Seven overexpressed genes associated with HCC prognosis and tumor-infiltrating antigen-presenting cells were identified as potential tumor antigens for the development of HCC mRNA vaccines. Two subtypes based on anoikis-related genes (ARGs) and two gene clusters with different characteristics were identified and validated in defined cohorts. The tumor immune microenvironment between the two subtypes showed different cell infiltration and molecular characteristics. Furthermore, a prognostic score based on seven lncRNAs identified by LASSO regression was constructed, with the low-risk group having favorable prognosis, a \u201chot\u201d immune microenvironment, and better response to immunotherapy. CCNB1, CDK1, DNASE1L3, KPNA2, PRC1, PTTG, and UBE2S were first identified as promising tumor antigens for mRNA vaccine development in HCC. Besides, we innovatively propose anoikis-based molecular subtypes, which not only enable personalized prognostic stratification of HCC patients but also provide a blueprint for identifying optimal candidates for tumor vaccines, enhancing immunotherapeutic strategies.<\/jats:p>","DOI":"10.1186\/s40537-023-00803-7","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T12:02:25Z","timestamp":1692187345000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of tumor antigens and anoikis-based molecular subtypes in the hepatocellular carcinoma immune microenvironment: implications for mRNA vaccine development and precision treatment"],"prefix":"10.1186","volume":"10","author":[{"given":"Zhiyuan","family":"Zheng","sequence":"first","affiliation":[]},{"given":"Hantao","family":"Yang","sequence":"additional","affiliation":[]},{"given":"Yang","family":"Shi","sequence":"additional","affiliation":[]},{"given":"Feng","family":"Zhou","sequence":"additional","affiliation":[]},{"given":"Lingxiao","family":"Liu","sequence":"additional","affiliation":[]},{"given":"Zhiping","family":"Yan","sequence":"additional","affiliation":[]},{"given":"Xiaolin","family":"Wang","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"issue":"3","key":"803_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10126","key":"803_CR2","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"10064","key":"803_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56\u201366.","journal-title":"Lancet"},{"issue":"1","key":"803_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-022-01706-6","volume":"22","author":"Y Tian","year":"2023","unstructured":"Tian Y, Xiao H, Yang Y, Zhang P, Yuan J, Zhang W, et al. Crosstalk between 5-methylcytosine and N(6)-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma. Mol Cancer. 2023;22(1):5.","journal-title":"Mol Cancer"},{"key":"803_CR5","doi-asserted-by":"publisher","DOI":"10.1159\/000528698","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wang M, Chen Q, Deng Y, Chen J, Dai Y, et al. Adverse events of immune checkpoint inhibitor-based therapies for unresectable hepatocellular carcinoma in prospective clinical trials: a systematic review and meta-analysis. Liver Cancer. 2023. https:\/\/doi.org\/10.1159\/000528698.","journal-title":"Liver Cancer."},{"issue":"2","key":"803_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","volume":"72","author":"AL Cheng","year":"2020","unstructured":"Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72(2):307\u201319.","journal-title":"J Hepatol"},{"issue":"2","key":"803_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.canlet.2008.05.029","volume":"272","author":"CD Simpson","year":"2008","unstructured":"Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett. 2008;272(2):177\u201385.","journal-title":"Cancer Lett"},{"issue":"32","key":"803_CR8","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1038\/s41388-022-02387-7","volume":"41","author":"Q Meng","year":"2022","unstructured":"Meng Q, Lu YX, Wei C, Wang ZX, Lin JF, Liao K, et al. Arginine methylation of MTHFD1 by PRMT5 enhances anoikis resistance and cancer metastasis. Oncogene. 2022;41(32):3912\u201324.","journal-title":"Oncogene"},{"issue":"12","key":"803_CR9","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1016\/j.bbamcr.2013.06.026","volume":"1833","author":"P Paoli","year":"2013","unstructured":"Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 2013;1833(12):3481\u201398.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"803_CR10","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/cdd.2008.190","volume":"16","author":"M Kochetkova","year":"2009","unstructured":"Kochetkova M, Kumar S, McColl SR. Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ. 2009;16(5):664\u201373.","journal-title":"Cell Death Differ"},{"issue":"11","key":"803_CR11","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1158\/2159-8290.CD-20-1690","volume":"11","author":"HF Zhang","year":"2021","unstructured":"Zhang HF, Hughes CS, Li W, He JZ, Surdez D, El-Naggar AM, et al. Proteomic screens for suppressors of anoikis identify IL1RAP as a promising surface target in ewing sarcoma. Cancer Discov. 2021;11(11):2884\u2013903.","journal-title":"Cancer Discov"},{"issue":"5","key":"803_CR12","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s11010-022-04384-6","volume":"477","author":"T Shi","year":"2022","unstructured":"Shi T, Zhang C, Xia S. The potential roles and mechanisms of non-coding RNAs in cancer anoikis resistance. Mol Cell Biochem. 2022;477(5):1371\u201380.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"803_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/1878-0261.12153","volume":"12","author":"OV Grinchuk","year":"2018","unstructured":"Grinchuk OV, Yenamandra SP, Iyer R, Singh M, Lee HK, Lim KH, et al. Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma. Mol Oncol. 2018;12(1):89\u2013113.","journal-title":"Mol Oncol"},{"issue":"19","key":"803_CR14","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa0804525","volume":"359","author":"Y Hoshida","year":"2008","unstructured":"Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359(19):1995\u20132004.","journal-title":"N Engl J Med"},{"issue":"5","key":"803_CR15","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2019.07.028","volume":"157","author":"A Moeini","year":"2019","unstructured":"Moeini A, Torrecilla S, Tovar V, Montironi C, Andreu-Oller C, Peix J, et al. An immune gene expression signature associated with development of human hepatocellular carcinoma identifies mice that respond to chemopreventive agents. Gastroenterology. 2019;157(5):1383-97.e11.","journal-title":"Gastroenterology"},{"issue":"4","key":"803_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0168-9525(97)01103-7","volume":"13","author":"M Rebhan","year":"1997","unstructured":"Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: integrating information about genes, proteins and diseases. Trends Genet. 1997;13(4):163.","journal-title":"Trends Genet"},{"key":"803_CR17","doi-asserted-by":"publisher","first-page":"baw100","DOI":"10.1093\/database\/baw100","volume":"2016","author":"AD Rouillard","year":"2016","unstructured":"Rouillard AD, Gundersen GW, Fernandez NF, Wang Z, Monteiro CD, McDermott MG, et al. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database (Oxford). 2016;2016:baw100.","journal-title":"Database (Oxford)."},{"issue":"5","key":"803_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"269","key":"803_CR19","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.","journal-title":"Sci Signal."},{"issue":"W1","key":"803_CR20","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556\u201360.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"803_CR21","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER20 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509\u201314.","journal-title":"Nucleic Acids Res"},{"key":"803_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"803_CR23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang L-G, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS"},{"issue":"3","key":"803_CR24","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2(3):100141.","journal-title":"Innovation (Camb)."},{"issue":"W1","key":"803_CR25","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):W216\u201321.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"803_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"W da Huang","year":"2009","unstructured":"da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44\u201357.","journal-title":"Nat Protoc"},{"issue":"1","key":"803_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248\u201362.","journal-title":"Cell Rep"},{"issue":"1","key":"803_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13073-020-0721-z","volume":"12","author":"J Fu","year":"2020","unstructured":"Fu J, Li K, Zhang W, Wan C, Zhang J, Jiang P, et al. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 2020;12(1):21.","journal-title":"Genome Med"},{"issue":"10","key":"803_CR29","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138.","journal-title":"Nat Med"},{"issue":"9","key":"803_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9): e107468.","journal-title":"PLoS ONE"},{"issue":"11","key":"803_CR31","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598\u2013608.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"803_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","volume":"20","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20(1):41.","journal-title":"Mol Cancer"},{"issue":"4","key":"803_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"803_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12943-021-01342-6","volume":"20","author":"X Huang","year":"2021","unstructured":"Huang X, Tang T, Zhang G, Liang T. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Mol Cancer. 2021;20(1):50.","journal-title":"Mol Cancer"},{"issue":"1","key":"803_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-021-01310-0","volume":"20","author":"X Huang","year":"2021","unstructured":"Huang X, Zhang G, Tang T, Liang T. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. Mol Cancer. 2021;20(1):44.","journal-title":"Mol Cancer"},{"issue":"1","key":"803_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40537-022-00641-z","volume":"9","author":"CP Gui","year":"2022","unstructured":"Gui CP, Li JY, Fu LM, Luo CG, Zhang C, Tang YM, et al. Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer. J Big Data. 2022;9(1):88.","journal-title":"J Big Data"},{"issue":"1","key":"803_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-020-01305-3","volume":"20","author":"R Du","year":"2021","unstructured":"Du R, Huang C, Liu K, Li X, Dong Z. Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy. Mol Cancer. 2021;20(1):15.","journal-title":"Mol Cancer"},{"issue":"2","key":"803_CR38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.canlet.2013.08.018","volume":"341","author":"I Horwacik","year":"2013","unstructured":"Horwacik I, Durbas M, Boratyn E, W\u0119grzyn P, Rokita H. Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells. Cancer Lett. 2013;341(2):248\u201364.","journal-title":"Cancer Lett"},{"issue":"9\u201310","key":"803_CR39","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s10495-018-1472-9","volume":"23","author":"M Durbas","year":"2018","unstructured":"Durbas M, Pabisz P, Wawak K, Wi\u015bniewska A, Boratyn E, Nowak I, et al. GD2 ganglioside-binding antibody 14G2a and specific aurora A kinase inhibitor MK-5108 induce autophagy in IMR-32 neuroblastoma cells. Apoptosis. 2018;23(9\u201310):492\u2013511.","journal-title":"Apoptosis"},{"issue":"23","key":"803_CR40","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-15-0293","volume":"21","author":"Y Liu","year":"2015","unstructured":"Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, et al. Combining an aurora kinase inhibitor and a death receptor ligand\/agonist antibody triggers apoptosis in melanoma cells and prevents tumor growth in preclinical mouse models. Clin Cancer Res. 2015;21(23):5338\u201348.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"803_CR41","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1158\/0008-5472.CAN-18-3397","volume":"79","author":"T Yin","year":"2019","unstructured":"Yin T, Zhao ZB, Guo J, Wang T, Yang JB, Wang C, et al. Aurora A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer. Cancer Res. 2019;79(13):3431\u201344.","journal-title":"Cancer Res"},{"key":"803_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.738841","volume":"11","author":"T Si","year":"2021","unstructured":"Si T, Huang Z, Jiang Y, Walker-Jacobs A, Gill S, Hegarty R, et al. Expression levels of three key genes CCNB1, CDC20, and CENPF in HCC are associated with antitumor immunity. Front Oncol. 2021;11: 738841.","journal-title":"Front Oncol"},{"issue":"9","key":"803_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13273","volume":"55","author":"B Li","year":"2022","unstructured":"Li B, Ge YZ, Yan WW, Gong B, Cao K, Zhao R, et al. DNASE1L3 inhibits proliferation, invasion and metastasis of hepatocellular carcinoma by interacting with \u03b2-catenin to promote its ubiquitin degradation pathway. Cell Prolif. 2022;55(9): e13273.","journal-title":"Cell Prolif"},{"issue":"1","key":"803_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12967-021-02709-5","volume":"19","author":"F Zeng","year":"2021","unstructured":"Zeng F, Luo L, Li D, Guo J, Guo M. KPNA2 interaction with CBX8 contributes to the development and progression of bladder cancer by mediating the PRDM1\/c-FOS pathway. J Transl Med. 2021;19(1):112.","journal-title":"J Transl Med"},{"issue":"9","key":"803_CR45","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1136\/gutjnl-2015-310625","volume":"65","author":"J Chen","year":"2016","unstructured":"Chen J, Rajasekaran M, Xia H, Zhang X, Kong SN, Sekar K, et al. The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt\/\u03b2-catenin signalling pathway. Gut. 2016;65(9):1522\u201334.","journal-title":"Gut"},{"issue":"1","key":"803_CR46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12943-018-0841-x","volume":"17","author":"JL Huang","year":"2018","unstructured":"Huang JL, Cao SW, Ou QS, Yang B, Zheng SH, Tang J, et al. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K\/AKT signaling in hepatocellular carcinoma. Mol Cancer. 2018;17(1):93.","journal-title":"Mol Cancer"},{"issue":"1","key":"803_CR47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41392-020-00432-z","volume":"6","author":"RY Zhang","year":"2021","unstructured":"Zhang RY, Liu ZK, Wei D, Yong YL, Lin P, Li H, et al. UBE2S interacting with TRIM28 in the nucleus accelerates cell cycle by ubiquitination of p27 to promote hepatocellular carcinoma development. Signal Transduct Target Ther. 2021;6(1):64.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"803_CR48","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1002\/jcb.26363","volume":"119","author":"E Kakavandi","year":"2018","unstructured":"Kakavandi E, Shahbahrami R, Goudarzi H, Eslami G, Faghihloo E. Anoikis resistance and oncoviruses. J Cell Biochem. 2018;119(3):2484\u201391.","journal-title":"J Cell Biochem"},{"issue":"2","key":"803_CR49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41418-021-00855-3","volume":"29","author":"Z Zhi","year":"2022","unstructured":"Zhi Z, Ouyang Z, Ren Y, Cheng Y, Liu P, Wen Y, et al. Non-canonical phosphorylation of Bmf by p38 MAPK promotes its apoptotic activity in anoikis. Cell Death Differ. 2022;29(2):323\u201336.","journal-title":"Cell Death Differ"},{"key":"803_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109684","volume":"115","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhu Z, Fu J, Liu X, Mi Z, Tao H, et al. Anoikis patterns exhibit distinct prognostic and immune landscapes in osteosarcoma. Int Immunopharmacol. 2023;115: 109684.","journal-title":"Int Immunopharmacol"},{"key":"803_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.847345","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu J, Hong M, Li Y, Chen D, Wu Y, Hu Y. Programmed cell death tunes tumor immunity. Front Immunol. 2022;13: 847345.","journal-title":"Front Immunol"},{"issue":"21","key":"803_CR52","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1158\/0008-5472.CAN-15-2011","volume":"75","author":"NC D'Amato","year":"2015","unstructured":"D\u2019Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, et al. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. Cancer Res. 2015;75(21):4651\u201364.","journal-title":"Cancer Res"},{"issue":"4","key":"803_CR53","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/1878-0261.12639","volume":"14","author":"C Yang","year":"2020","unstructured":"Yang C, Huang X, Liu Z, Qin W, Wang C. Metabolism-associated molecular classification of hepatocellular carcinoma. Mol Oncol. 2020;14(4):896\u2013913.","journal-title":"Mol Oncol"},{"issue":"1","key":"803_CR54","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/cam4.4858","volume":"12","author":"J Huo","year":"2023","unstructured":"Huo J, Cai J, Wu L. Comprehensive analysis of metabolic pathway activity subtypes derived prognostic signature in hepatocellular carcinoma. Cancer Med. 2023;12(1):898\u2013912.","journal-title":"Cancer Med"},{"issue":"1","key":"803_CR55","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13046-020-01687-8","volume":"39","author":"H Zhang","year":"2020","unstructured":"Zhang H, Zhu C, He Z, Chen S, Li L, Sun C. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p\/STAT1\/PD-L1 axis. J Exp Clin Cancer Res. 2020;39(1):179.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"803_CR56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13046-020-01664-1","volume":"39","author":"H He","year":"2020","unstructured":"He H, Wang Y, Ye P, Yi D, Cheng Y, Tang H, et al. Long noncoding RNA ZFPM2-AS1 acts as a miRNA sponge and promotes cell invasion through regulation of miR-139\/GDF10 in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39(1):159.","journal-title":"J Exp Clin Cancer Res"},{"issue":"45","key":"803_CR57","doi-asserted-by":"publisher","first-page":"5982","DOI":"10.1038\/s41388-018-0387-9","volume":"37","author":"F Kong","year":"2018","unstructured":"Kong F, Deng X, Kong X, Du Y, Li L, Zhu H, et al. ZFPM2-AS1, a novel lncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF. Oncogene. 2018;37(45):5982\u201396.","journal-title":"Oncogene"},{"issue":"9","key":"803_CR58","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41419-020-02810-5","volume":"11","author":"L Wang","year":"2020","unstructured":"Wang L, Bo X, Yi X, Xiao X, Zheng Q, Ma L, et al. Exosome-transferred LINC01559 promotes the progression of gastric cancer via PI3K\/AKT signaling pathway. Cell Death Dis. 2020;11(9):723.","journal-title":"Cell Death Dis"},{"issue":"4","key":"803_CR59","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41419-021-03571-5","volume":"12","author":"H Shen","year":"2021","unstructured":"Shen H, Zhu H, Chen Y, Shen Z, Qiu W, Qian C, et al. ZEB1-induced LINC01559 expedites cell proliferation, migration and EMT process in gastric cancer through recruiting IGF2BP2 to stabilize ZEB1 expression. Cell Death Dis. 2021;12(4):349.","journal-title":"Cell Death Dis"},{"issue":"4","key":"803_CR60","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1002\/jcp.29288","volume":"235","author":"C Lou","year":"2020","unstructured":"Lou C, Zhao J, Gu Y, Li Q, Tang S, Wu Y, et al. LINC01559 accelerates pancreatic cancer cell proliferation and migration through YAP-mediated pathway. J Cell Physiol. 2020;235(4):3928\u201338.","journal-title":"J Cell Physiol"},{"key":"803_CR61","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.neucom.2022.04.083","volume":"494","author":"T Dokeroglu","year":"2022","unstructured":"Dokeroglu T, Deniz A, Kiziloz HE. A comprehensive survey on recent metaheuristics for feature selection. Neurocomputing. 2022;494:269\u201396.","journal-title":"Neurocomputing"},{"issue":"6","key":"803_CR62","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1016\/j.apsb.2021.11.021","volume":"12","author":"W Wang","year":"2022","unstructured":"Wang W, Feng S, Ye Z, Gao H, Lin J, Ouyang D. Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm. Acta Pharm Sin B. 2022;12(6):2950\u201362.","journal-title":"Acta Pharm Sin B"}],"container-title":["Journal of Big Data"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40537-023-00803-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40537-023-00803-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40537-023-00803-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T09:05:43Z","timestamp":1700384743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalofbigdata.springeropen.com\/articles\/10.1186\/s40537-023-00803-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1186\/s40537-023-00803-7","relation":{},"ISSN":["2196-1115"],"issn-type":[{"value":"2196-1115","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,16]]},"assertion":[{"value":"12 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no potential competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}